Received Feb 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
New onset MF; This is a literature report for the following literature source(s). A 63-year-old male presented in May 2022 with a chief complaint of a rash located on his left scalp, left forehead, right hand, and scalp. This patient had a new onset diagnosis of MF. His lesions began about one year prior, following COVID-19 vaccination in May 2021; he had no prior skin symptoms. He initially tried topical and oral steroids and oral antibiotics, which reduced his itching but not the skin eruption. Multiple skin biopsies were taken in April 2022, and 4 out 5 of the biopsies showed mycosis fungoides, with the scalp showing transformed mycosis fungoides. This patient was started on oral bexarotene, 93 pralatrexate, and brentuximab but continued to progress with tumors. Repeat skin biopsy from June 2023 demonstrated MF with large cell transformation. In October 2023 he had a stem cell transplant. In December 2023, roughly two years after COVID-19 vaccinations, he exhibited recurrence on the skin. He was enrolled in a clinical trial of a CDK9 inhibitor but progressed quickly with multiple new lesions. He completed a CAR-T CD5 cell treatment, which also was unsuccessful. He restarted romidepsin in October 2024. His disease remains significant yet stable and a second stem cell transplant was completed March 2025.; Sender's Comments: As there is limited information in the case provided, the causal association between the reported serious event: Cutaneous T-cell lymphoma (NEW ONSET MF) and the suspect drug BNT162B2 cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-PV202600013864 Same article/ drug and different patient/event;
Test Date: 202204; Test Name: Multiple skin biopsies; Result Unstructured Data: Test Result:4 out 5 of the biopsies showed mycosis fungoides,; Comments: with the scalp showing transformed mycosis fungoides.; Test Date: 202306; Test Name: Multiple skin biopsies; Result Unstructured Data: Test Result:demonstrated MF with large cell transformation